EP Patent

EP3024455A1 — Sgc stimulators or sgc activators and pde5 inhibitors in combination with additional treatment for the therapy of cystic fibrosis

Assigned to Bayer Pharma AG · Expires 2016-06-01 · 10y expired

What this patent protects

The present invention relates to soluble guanylate cyclase (sGC) stimulators or activators with phosphodiesterase-5 (PDE5) inhibitors and at least one other pharmacological compound for the preparation of medicaments for the treatment of Cystic Fibrosis (CF).

USPTO Abstract

The present invention relates to soluble guanylate cyclase (sGC) stimulators or activators with phosphodiesterase-5 (PDE5) inhibitors and at least one other pharmacological compound for the preparation of medicaments for the treatment of Cystic Fibrosis (CF).

Drugs covered by this patent

Patent Metadata

Patent number
EP3024455A1
Jurisdiction
EP
Classification
—
Expires
2016-06-01
Drug substance claim
No
Drug product claim
No
Assignee
Bayer Pharma AG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.